DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



BAYQ3939, 1000 mg Tablet in Transrectal Needle Biopsies of the Prostate (TRNBP) - Infection Prophylaxis

Information source: Bayer
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Infection

Intervention: Ciprofloxacin single dose (Drug); Ciprofloxacin triple dose (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Bayer

Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer

Summary

The primary purpose of this clinical trial is to compare in a double-blind randomized trial, the efficacy and safety of ciprofloxacin MR 1000 mg tablets given as a single-dose or as a multiple-dose regimen for the prevention of infectious complications in patients undergoing transrectal needle biopsies of the prostate (TRNBP).

Clinical Details

Official title: Prospective, Randomized, Double-Blind, Comparison of Ciprofloxacin Extended-Release 1000 mg Tablets Given as Two Different Prophylactic Dosing Regimens

Study design: Prevention, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: Bacteriological Response (bacteriuria vs. no bacteriuria)

Secondary outcome:

Clinical Response (patients without clinical symptoms or signs of bacteriuria vs. patients with clinical symptoms or signs of bacteriuria)

Incidence of post-procedure GU tract infections other than bacteriuria

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Male.

Criteria:

Inclusion Criteria:

- Males.

- 18-years of age or older.

- Transrectal needle biopsy of the prostate required.

- A clean-catch midstream-urine (MSU) culture negative (<104 CFU/mL) for possible

pathogens at the Pre-Therapy Visit prior to the TRNBP.

- Gastrointestinal absorption is adequate as evidenced by passage of gas or feces per

rectum and patient can tolerate oral food, fluids, and medication without vomiting or diarrhea.

Exclusion Criteria:

- History of hypersensitivity to ciprofloxacin or other quinolone antibiotics

- Valvular heart disease that requires antibiotic prophylaxis to prevent bacterial

endocarditis

- Concomitant use of theophylline, probenecid, or warfarin at any time during the entire

study

- Renal insufficiency

- Known or suspected central nervous system disorder that may predispose to seizures or

lower the seizure threshold

- Absolute neutrophil count (ANC) <1000/mm3

- Human immunodeficiency virus (HIV) infection with a CD4 count <200 cells/μL. HIV

testing is NOT required

- Antibiotic administration within one week of the TRNBP

- Severe hepatic insufficiency (Child-Pugh C)

Locations and Contacts

Rio de Janeiro, Brazil

São Paulo 04039-004, Brazil

Quebec G1S 2L6, Canada

Milano 20132, Italy

Roma 00155, Italy

Padova 35128, Italy

Bergamo 24128, Italy

Monterrey 64320, Mexico

México, D.F. 07760, Mexico

México, D. F. 06700, Mexico

Barcelona 08035, Spain

Madrid 28034, Spain

Sevilla 41014, Spain

Valencia 46009, Spain

Birmingham, Alabama 35209, United States

Calgary, Alberta T2V 4R6, Canada

Edmonton, Alberta T6G 2C8, Canada

Victoria, British Columbia V8R 6T9, Canada

San Diego, California 92101, United States

Sherman Oaks, California 91403, United States

San Francisco, California 94117, United States

Waterbury, Connecticut 06708, United States

Ocala, Florida 34474, United States

Atlanta, Georgia 30342, United States

Roswell, Georgia 30076, United States

Chicago, Illinois 60611, United States

Zapopan, Jalisco 45170, Mexico

Hopedale, Massachusetts 01747, United States

Belo Horizonte, Minas Gerais, Brazil

Cincinnati, Ohio 45212-2787, United States

Columbus, Ohio 43214-1419, United States

Toronto, Ontario M4H 1C3, Canada

Toronto, Ontario M4N 3M5, Canada

Hamilton, Ontario L8N 1T8, Canada

London, Ontario N6A 4V2, Canada

Philadelphia, Pennsylvania 19107, United States

Vigo, Pontevedra 36214, Spain

Sherbrooke, Quebec J1H 5N4, Canada

Chicoutimi, Quebec G7H 1H2, Canada

Laval, Quebec H7G 2E6, Canada

Porto Alegre, RS 90470 340, Brazil

Simpsonville, South Carolina 29681, United States

Villahermosa, Tabasco 86158, Mexico

San Antonio, Texas 78229, United States

Norfolk, Virginia 23510, United States

Spokane, Washington 99202, United States

Additional Information

Click here to find results for studies related to marketed products

Click here and search for drug information provided by the FDA

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product

Starting date: April 2004
Ending date: October 2004
Last updated: April 29, 2008

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009